Study results demonstrated that Silver Bullet Therapeutics’ OrthoFuzIon® Antimicrobial Bone Screw was able to significantly disrupt the development of biofilms compared to traditional, uncoated titanium screws.
The study was designed to test the “Time Kill” and “Adherence” effectiveness of OrthoFuzIon against the top six antibiotic resistant “superbugs” as identified by the CDC, including Carbapenem-resistant Enterobacteriaceae, Klebsiella pneumoniae, Methicillin-resistant Staphylococcus aureus, ESBL-producing Enterobacteriaceae (extended-spectrum β-lactamases), Escherichia coli, Vancomycin-resistant Enterococcus, Enterococcus faecium, Multidrug-resistant Pseudomonas aeruginosa and Multidrug-resistant Acinetobacter baumannii.
OrthoFuzIon is one of the first antimicrobial implantable medical devices designed specifically for orthopaedics. The implant received CE Mark approval in early 2015 and is amassing a portfolio of patents in the U.S.
Sources: Silver Bullet Therapeutics, Inc.; ORTHOWORLD Inc.
Study results demonstrated that Silver Bullet Therapeutics' OrthoFuzIon® Antimicrobial Bone Screw was able to significantly disrupt the development of biofilms compared to traditional, uncoated titanium screws.
The study was designed to test the “Time Kill” and “Adherence” effectiveness of OrthoFuzIon against the top six antibiotic resistant...
Study results demonstrated that Silver Bullet Therapeutics’ OrthoFuzIon® Antimicrobial Bone Screw was able to significantly disrupt the development of biofilms compared to traditional, uncoated titanium screws.
The study was designed to test the “Time Kill” and “Adherence” effectiveness of OrthoFuzIon against the top six antibiotic resistant “superbugs” as identified by the CDC, including Carbapenem-resistant Enterobacteriaceae, Klebsiella pneumoniae, Methicillin-resistant Staphylococcus aureus, ESBL-producing Enterobacteriaceae (extended-spectrum β-lactamases), Escherichia coli, Vancomycin-resistant Enterococcus, Enterococcus faecium, Multidrug-resistant Pseudomonas aeruginosa and Multidrug-resistant Acinetobacter baumannii.
OrthoFuzIon is one of the first antimicrobial implantable medical devices designed specifically for orthopaedics. The implant received CE Mark approval in early 2015 and is amassing a portfolio of patents in the U.S.
Sources: Silver Bullet Therapeutics, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.